JP6454323B2 - 粒子状結晶性材料のコンディショニングのための方法及びシステム - Google Patents
粒子状結晶性材料のコンディショニングのための方法及びシステム Download PDFInfo
- Publication number
- JP6454323B2 JP6454323B2 JP2016503111A JP2016503111A JP6454323B2 JP 6454323 B2 JP6454323 B2 JP 6454323B2 JP 2016503111 A JP2016503111 A JP 2016503111A JP 2016503111 A JP2016503111 A JP 2016503111A JP 6454323 B2 JP6454323 B2 JP 6454323B2
- Authority
- JP
- Japan
- Prior art keywords
- conditioning
- gas
- zone
- conditioning gas
- micronized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003750 conditioning effect Effects 0.000 title claims description 585
- 238000000034 method Methods 0.000 title claims description 201
- 239000002178 crystalline material Substances 0.000 title claims description 135
- 239000007789 gas Substances 0.000 claims description 438
- 239000000463 material Substances 0.000 claims description 255
- 239000002245 particle Substances 0.000 claims description 160
- 230000001143 conditioned effect Effects 0.000 claims description 110
- 238000002156 mixing Methods 0.000 claims description 94
- 239000002904 solvent Substances 0.000 claims description 93
- 239000011236 particulate material Substances 0.000 claims description 77
- 238000000137 annealing Methods 0.000 claims description 55
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical group [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 35
- 239000013543 active substance Substances 0.000 claims description 29
- 239000003960 organic solvent Substances 0.000 claims description 28
- 238000002347 injection Methods 0.000 claims description 24
- 239000007924 injection Substances 0.000 claims description 24
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 21
- 229960004436 budesonide Drugs 0.000 claims description 21
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 claims description 20
- 229960002462 glycopyrronium bromide Drugs 0.000 claims description 20
- 239000012159 carrier gas Substances 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 17
- 239000013557 residual solvent Substances 0.000 claims description 17
- 239000003125 aqueous solvent Substances 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 13
- 238000000926 separation method Methods 0.000 claims description 13
- 239000006185 dispersion Substances 0.000 claims description 12
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 238000004891 communication Methods 0.000 claims description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 230000004888 barrier function Effects 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000002198 insoluble material Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 claims description 2
- DCYGAPKNVCQNOE-UHFFFAOYSA-N 2,2,2-triphenylacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)O)C1=CC=CC=C1 DCYGAPKNVCQNOE-UHFFFAOYSA-N 0.000 claims description 2
- WBJWXIQDBDZMAW-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carbonyl chloride Chemical compound C1=CC=CC2=C(C(Cl)=O)C(O)=CC=C21 WBJWXIQDBDZMAW-UHFFFAOYSA-N 0.000 claims description 2
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 claims description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- PYHXGXCGESYPCW-UHFFFAOYSA-N alpha-phenylbenzeneacetic acid Natural products C=1C=CC=CC=1C(C(=O)O)C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 239000010419 fine particle Substances 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000001630 malic acid Substances 0.000 claims description 2
- 235000011090 malic acid Nutrition 0.000 claims description 2
- 239000013080 microcrystalline material Substances 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 239000002195 soluble material Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- XDXFALYQLCMAQN-BTJKTKAUSA-N butanedioic acid;(z)-but-2-enedioic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)\C=C/C(O)=O XDXFALYQLCMAQN-BTJKTKAUSA-N 0.000 claims 1
- 230000008569 process Effects 0.000 description 61
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 58
- 229940015042 glycopyrrolate Drugs 0.000 description 48
- 238000009826 distribution Methods 0.000 description 41
- 239000003246 corticosteroid Substances 0.000 description 25
- -1 for example Substances 0.000 description 24
- 239000007788 liquid Substances 0.000 description 23
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 22
- 229930006000 Sucrose Natural products 0.000 description 22
- 229960004793 sucrose Drugs 0.000 description 22
- 239000005720 sucrose Substances 0.000 description 21
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 238000001179 sorption measurement Methods 0.000 description 15
- 230000002776 aggregation Effects 0.000 description 13
- 230000008859 change Effects 0.000 description 13
- 238000002425 crystallisation Methods 0.000 description 13
- 230000008025 crystallization Effects 0.000 description 13
- 229960002714 fluticasone Drugs 0.000 description 13
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 238000000227 grinding Methods 0.000 description 12
- 239000006199 nebulizer Substances 0.000 description 12
- 229960000289 fluticasone propionate Drugs 0.000 description 11
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 238000004220 aggregation Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 238000005070 sampling Methods 0.000 description 10
- 229940126062 Compound A Drugs 0.000 description 9
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 9
- 238000001704 evaporation Methods 0.000 description 9
- 230000008020 evaporation Effects 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 238000000889 atomisation Methods 0.000 description 8
- 229960001334 corticosteroids Drugs 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 230000007704 transition Effects 0.000 description 8
- 239000012190 activator Substances 0.000 description 7
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000004320 controlled atmosphere Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 230000009477 glass transition Effects 0.000 description 7
- 238000003801 milling Methods 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 229960002052 salbutamol Drugs 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 229910001220 stainless steel Inorganic materials 0.000 description 7
- 239000010935 stainless steel Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 6
- 238000000635 electron micrograph Methods 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000010902 jet-milling Methods 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000001878 scanning electron micrograph Methods 0.000 description 6
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000003149 muscarinic antagonist Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 4
- 229930003347 Atropine Natural products 0.000 description 4
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 4
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 4
- 229960000396 atropine Drugs 0.000 description 4
- 229940125388 beta agonist Drugs 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- 229960001022 fenoterol Drugs 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000011261 inert gas Substances 0.000 description 4
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 229960002657 orciprenaline Drugs 0.000 description 4
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- BKLAJZNVMHLXAP-VKGMXUHCSA-N 3-[(1r,5s)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl]-2,2-diphenylpropanenitrile Chemical compound C([C@H]1CC[C@@H](C2)[N+]1(C)C)C2CC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 BKLAJZNVMHLXAP-VKGMXUHCSA-N 0.000 description 3
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 3
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 3
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 3
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 3
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 3
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 3
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 150000003842 bromide salts Chemical class 0.000 description 3
- 229960003728 ciclesonide Drugs 0.000 description 3
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 3
- 229960004993 dimenhydrinate Drugs 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229960002179 ephedrine Drugs 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 229960002848 formoterol Drugs 0.000 description 3
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 229960001317 isoprenaline Drugs 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 229960001664 mometasone Drugs 0.000 description 3
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229960000797 oxitropium Drugs 0.000 description 3
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 3
- 229960004633 pirenzepine Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 229960004017 salmeterol Drugs 0.000 description 3
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 3
- 229960002646 scopolamine Drugs 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 3
- 229940110309 tiotropium Drugs 0.000 description 3
- 229960004791 tropicamide Drugs 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000048 adrenergic agonist Substances 0.000 description 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 2
- 229960001081 benzatropine Drugs 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004581 coalescence Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- FVTWTVQXNAJTQP-UHFFFAOYSA-N diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol Chemical compound C=1C=CC=CC=1C(C12CC[N+](CCOCC=3C=CC=CC=3)(CC1)CC2)(O)C1=CC=CC=C1 FVTWTVQXNAJTQP-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960000676 flunisolide Drugs 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- 229960001888 ipratropium Drugs 0.000 description 2
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Chemical compound CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 229960000195 terbutaline Drugs 0.000 description 2
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 description 2
- 229960001491 trospium Drugs 0.000 description 2
- 229960004258 umeclidinium Drugs 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- RRGKLLSQTYKKQM-MHZLTWQESA-N 7-[(1r)-2-[2-[2-fluoro-5-[[4-(2-propan-2-yl-1,3-thiazole-4-carbonyl)-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl]methyl]phenyl]ethylamino]-1-hydroxyethyl]-4-hydroxy-3h-1,3-benzothiazol-2-one Chemical compound S1C(C(C)C)=NC(C(=O)N2CC3(CCN(CC=4C=C(CCNC[C@H](O)C=5C=6SC(=O)NC=6C(O)=CC=5)C(F)=CC=4)CC3)OCC2)=C1 RRGKLLSQTYKKQM-MHZLTWQESA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 102000006463 Talin Human genes 0.000 description 1
- 108010083809 Talin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960003060 bambuterol Drugs 0.000 description 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 229950000210 beclometasone dipropionate Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229960004620 bitolterol Drugs 0.000 description 1
- FZGVEKPRDOIXJY-UHFFFAOYSA-N bitolterol Chemical compound C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)CNC(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 FZGVEKPRDOIXJY-UHFFFAOYSA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960001386 carbuterol Drugs 0.000 description 1
- KEMXXQOFIRIICG-UHFFFAOYSA-N carbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(NC(N)=O)=C1 KEMXXQOFIRIICG-UHFFFAOYSA-N 0.000 description 1
- 229950010713 carmoterol Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- DMLFJMQTNDSRFU-UHFFFAOYSA-N chlordiazepoxide hydrochloride Chemical compound Cl.O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 DMLFJMQTNDSRFU-UHFFFAOYSA-N 0.000 description 1
- 229960001117 clenbuterol Drugs 0.000 description 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
- 230000001632 homeopathic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229960004078 indacaterol Drugs 0.000 description 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000003317 industrial substance Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 229950008204 levosalbutamol Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229950001768 milveterol Drugs 0.000 description 1
- BMKINZUHKYLSKI-DQEYMECFSA-N n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-[[(2r)-2-hydroxy-2-phenylethyl]amino]phenyl]ethylamino]ethyl]phenyl]formamide Chemical compound C1([C@@H](O)CNC2=CC=C(C=C2)CCNC[C@H](O)C=2C=C(NC=O)C(O)=CC=2)=CC=CC=C1 BMKINZUHKYLSKI-DQEYMECFSA-N 0.000 description 1
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 229960002720 reproterol Drugs 0.000 description 1
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229940125390 short-acting beta agonist Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
- B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
- B02C19/00—Other disintegrating devices or methods
- B02C19/06—Jet mills
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Combustion & Propulsion (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Nozzles (AREA)
- Glass Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
別段の定義がされない限り、本明細書において使用される用語は、当技術分野において理解されるそれらの通常の意味を有する。明確にするため、以下の用語を詳細に定義する。
図1は、本明細書による粒子状結晶性材料をコンディショニングするためのシステムの実施形態の概略図を示す。システム100は送出ゾーン110を含み、ここでは1つ又は複数の結晶性材料(例えば、1つ又は複数の薬学活性剤又は薬学的に許容可能な賦形剤若しくは補助剤)をコンディショニングガスと混合するために送出及び準備してもよい。システムはコンディショニングガス供給ゾーン120も含む。コンディショニングガスはコンディショニングガス供給ゾーン120から供給され、特定の実施形態では、コンディショニングガスはコンディショニングガス供給ゾーン120内で生成される。結晶性粒子状材料及びコンディショニングガスを混合ゾーン130へ導入してもよく、その後それらはコンディショニングゾーン140へ入る。コンディショニングゾーン140は、コンディショニング室内に収容され保持されている制御された雰囲気を含む。制御された雰囲気は、コンディショニングガス、及び結晶性粒子状材料を送るのに使用される任意の送出ガスを含み、コンディショニングされる粒子状材料はコンディショニング室内の制御された雰囲気内で同伴、懸濁、又はエアロゾル化されたままである。結晶性材料は、コンディショニングゾーン140内で所望の滞留時間で保持されながら、コンディショニングゾーン140内でアニーリングプロセスを受ける。微細化材料を分離及び収集ゾーン150でコンディショニングガスから分離しコンディショニングゾーン140から収集してもよく、分離及び収集ゾーン150は、微細化材料の収集に適しているいくつかの良く知られた部材のいずれかを含んでいてもよい。
粒子状結晶性材料をコンディショニングするための方法も本明細書において提供される。本明細書による方法は、本明細書で提供されるコンディショニングシステムを使用して行うことができる。一般に、本明細書に記載の方法は、(1)結晶性粒子状材料を生成及び/又は準備するステップと;(2)粒子状材料を、コンディショニングガスと混合される雰囲気中に導入するステップと;(3)粒子状材料を所望の滞留時間の間コンディショニングガスと接触させたままにしておくステップと;(4)コンディショニング済み粒子状材料を収集するステップとを含む。具体的な実施形態において、粒子状材料は微細化結晶性材料である。本明細書に記載の方法を使用してコンディショニングすることができる材料の例としては、前述の材料が挙げられる。本明細書による方法の特定の実施形態において、コンディショニングしようとする材料は、典型的にはコンディショニングガスと混合されている送出ガス内に同伴又はエアロゾル化され、粒子状材料は、コンディショニングゾーンを通って移動する際に、コンディショニングガス中に同伴、懸濁、又はエアロゾル化されたままである。コンディショニングガスの性質及びコンディショニングゾーン内での粒子状材料の滞留時間は、材料のアニーリングを実現するように制御される。
具体的な実施形態において、本明細書に従って粒子状結晶性材料(例えば、微細化結晶性材料)をコンディショニングするための方法は、エアロゾル化微細化結晶性粒子を準備するステップであって、前記微細化結晶性粒子がアモルファス材料及び残留溶媒の一方又は両方を含有する、ステップと;微細化装置の出口に直接接続された室内で、微細化結晶性粒子を、キャリアガス及びコンディショニング蒸気を含むコンディショニングガスと連続的に混合するステップと;微細化結晶性粒子を、前記微細化結晶性粒子のアニーリングを生じさせるのに十分な時間でコンディショニングガスと接触を維持するステップであって、前記アニーリングが相転移を生じさせる、ステップと;微細化結晶性粒子をコンディショニングガスから分離するステップとを含む。本明細書において詳細に述べるように、そのような相転移は粒子状結晶性材料中に存在する結晶のバルク中の変化を指す。そのような実施形態において、相転移は、結晶化の溶媒の除去、結晶化の溶媒の交換、アモルファスから結晶への相変化、又は単なるアモルファスから結晶への相変化を超えた物理構造の変化から選択されてもよい。
実施例2及び3は、アニーリングを促進するために気化した有機溶媒(エタノール)を含有するコンディショニングガスを使用した、水不溶性分子のプロセス内コンディショニングの例を提供する。ブデソニド及びプロピオン酸フルチカゾンを代表的な化合物として選択した。対応するエタノール収着等温線を測定することによりエタノール雰囲気下でアモルファス部分の結晶化を促進することになる条件を選択することによって、アニーリング条件を決定した。
Claims (45)
- 1つの微細化結晶性材料をコンディショニングする方法であって、
微細化結晶性粒子を送出ガス内でエアロゾル化するステップであって、前記微細化結晶性粒子がアモルファス材料及び残留溶媒の一方又は両方を含有する、ステップと;
室内で(in a chamber)、微細化結晶性粒子を、キャリアガス及び溶媒蒸気を含むコンディショニングガスと連続的に混合するステップと;
エアロゾル化微細化結晶性粒子を、前記微細化結晶性粒子のアニーリングを生じさせるのに十分な時間でコンディショニングガスと接触を維持するステップであって、前記アニーリングがアモルファス材料の存在の低減又は残留溶媒の量の低減の一方又は両方をもたらす、ステップと;
微細化結晶性粒子をコンディショニングガスから分離するステップと
を含む、方法。 - 微細化結晶性粒子が約0.1〜600秒間コンディショニングガスと混合される、請求項1に記載の方法。
- 微細化結晶性粒子が約2〜6秒間コンディショニングガスと混合される、請求項1に記載の方法。
- 微細化結晶性粒子が約3秒間コンディショニングガスと混合される、請求項2に記載の方法。
- 微細化結晶性粒子が水溶性であり、コンディショニングガス中に含まれる溶媒蒸気が水性溶媒蒸気であり、約20℃〜100℃の範囲の温度及び相対湿度が約0.05%〜95%の範囲であるコンディショニングガスが供給される、請求項1に記載の方法。
- 微細化結晶性粒子が非水溶性であり、コンディショニングガス中に含まれる溶媒蒸気が有機溶媒蒸気であり、約20℃〜100℃の範囲の温度及び非水性溶媒の相対飽和度が約0.05%〜95%の範囲であるコンディショニングガスが供給される、請求項1に記載の方法。
- 微細化結晶性粒子が水溶性材料と非水溶性材料の混合物であり、コンディショニングガス中に含まれる溶媒蒸気が水性溶媒蒸気及び有機溶媒蒸気を含み、約10℃〜100℃の範囲の温度並びに水性溶媒の相対湿度が約0.05%〜95%の範囲及び非水性溶媒の相対飽和度が約0.05%〜95%の範囲であるコンディショニングガスが供給される、請求項1に記載の方法。
- 微細化結晶性粒子がジェットミルを使用して製造され、送出ガスがジェットミルを出るガス流を含む、請求項1から7のいずれか一項に記載の方法。
- コンディショニングガスが、約1〜10部のコンディショニングガスと約1部のエアロゾル化微細化結晶性粒子の比で、エアロゾル化微細化結晶性粒子と混合される、請求項1から8のいずれか一項に記載の方法。
- 約20標準立方フィート毎分(SCFM)から約500SCFMまでの範囲の流量でコンディショニングガスを供給すること、及び約20SCFMから75SCFMまでの流量で送出ガスを供給することにより、コンディショニングガスが送出ガスと混合される、請求項1から9のいずれか一項に記載の方法。
- 微細化結晶性粒子が約0.1μm〜約100μmの範囲の粒径を有する、請求項1から10のいずれか一項に記載の方法。
- コンディショニングガスが、微細化結晶性粒子と混合される間、約25標準立方フィート毎分(SCFM)から約300SCFMまでの範囲の流量で供給される、請求項1から11のいずれか一項に記載の方法。
- エアロゾル化微細化結晶性粒子が、コンディショニングガスと混合される間、約25標準立方フィート毎分(SCFM)から約200SCFMまでの範囲の流量で供給される、請求項1から12のいずれか一項に記載の方法。
- コンディショニングガスが窒素ガスを含む、請求項1から13のいずれか一項に記載の方法。
- 微細化結晶性粒子が密室内でコンディショニングガスと混合される、請求項1から14のいずれか一項に記載の方法。
- 1つの微細化結晶性材料のプロセス内コンディショニングのためのシステムであって、
1つの結晶性材料を微細化するためのデバイスを含む微細化ゾーンと;
微細化ゾーンと流体連通している混合ゾーンであって、該微細化結晶性材料が微細化ゾーンから混合ゾーンへ送られそこでコンディショニングガスと混合される、混合ゾーンと;
混合ゾーンと流体連通しているコンディショニングガス供給ゾーンであって、所望の温度及び溶媒蒸気濃度でコンディショニングガスを混合ゾーンへ供給して該微細化結晶性材料と混合させる、コンディショニングガス供給ゾーンと;
混合ゾーンと流体連通しているコンディショニングゾーンであって、少なくとも1つの微細化結晶性材料とコンディショニングガスの混合物がコンディショニングゾーンに送られ所望の滞留時間の間維持される、コンディショニングゾーンと;
コンディショニング済み微細化結晶性材料がコンディショニングガスから分離されコンディショニング済み活性剤が収集される、分離及び収集ゾーンと
を含む、システム。 - 微細化結晶性材料が水溶性であり、コンディショニングガス供給ゾーンが、約20℃〜100℃の範囲の温度及び相対湿度が約0.05%〜95%の範囲であるコンディショニングガスを供給するように構成されている、請求項16に記載のシステム。
- 微細化結晶性材料が非水溶性であり、コンディショニングガス供給ゾーンが、約20℃〜100℃の範囲の温度及び流動するコンディショニングガス流中の非水性溶媒の相対飽和度が約0.05%〜90%の範囲であるコンディショニングガスを供給するように構成されている、請求項16に記載のシステム。
- 微細化結晶性材料が水溶性材料と非水溶性材料の混合物であり、コンディショニングガス供給ゾーンが、約20℃〜30℃の範囲の温度並びに流動するコンディショニングガス流中の相対湿度が50〜75%及び非水性溶媒の相対飽和度が約50%〜75%の範囲であるコンディショニングガスを供給するように構成されている、請求項16に記載のシステム。
- コンディショニングガス供給ゾーンが、約25℃の温度及び相対湿度が約65%であるコンディショニングガスを供給するように構成されている、請求項16に記載のシステム。
- コンディショニングゾーンが、少なくとも1つの微細化結晶性材料とコンディショニングガスの混合物を約0.5〜60秒の滞留時間でコンディショニングゾーン内に維持するように構成されている、請求項16に記載のシステム。
- コンディショニングゾーンが、少なくとも1つの微細化結晶性材料とコンディショニングガスの混合物を約1〜約10秒の滞留時間でコンディショニングゾーン内に維持するように構成されている、請求項16に記載のシステム。
- コンディショニングゾーンが、少なくとも1つの微細化結晶性材料とコンディショニングガスの混合物を約3秒の滞留時間でコンディショニングゾーン内に維持するように構成されている、請求項16に記載のシステム。
- 微細化ゾーンが、少なくとも1つの結晶性材料を微細化するように構成されたジェットミルを含む、請求項16に記載のシステム。
- コンディショニングガス供給ゾーンが、約150標準立方フィート毎分(SCFM)から約300SCFMまでの範囲の流量でコンディショニングガスを混合ゾーンへ供給するように構成されている、請求項16に記載のシステム。
- 微細化ゾーンが、約35標準立方フィート毎分(SCFM)から約200SCFMまでの範囲の流量で、少なくとも1つの微細化結晶性材料をエアロゾル化粒子状材料として混合ゾーンへ送るように構成されている、請求項16に記載のシステム。
- 混合ゾーンが分散ヘッド組立体を含み、コンディショニングガス及び微細化結晶性材料が分散ヘッド組立体で混合される、請求項16に記載のシステム。
- 分散ヘッド組立体が、コンディショニングガス及び少なくとも1つの微細化結晶性材料の混合を制御するように構成された混合ヘッドを含む、請求項27に記載のシステム。
- 混合ヘッドが、コンディショニングガスを注入ノズルへ送るように構成された注入ノズル入口を含み、混合ヘッドが、微細化結晶性材料を注入ノズルへ送るように構成された送出ガス入口を含み、注入ノズルが、コンディショニングガスを少なくとも1つの微細化結晶性材料と混合させるように構成されている、請求項28に記載のシステム。
- 微細化結晶性材料とコンディショニングガスの混合物のコンディショニングゾーンにおける滞留時間は、コンディショニングゾーンの形状を調整することにより改変することができる、請求項16に記載のシステム。
- 微細化結晶性材料とコンディショニングガスの混合物のコンディショニングゾーンにおける滞留時間は、微細化結晶性材料とコンディショニングガスの混合物が混合ゾーンからコンディショニングゾーンへ送られる速度を調整することにより改変することができる、請求項16に記載のシステム。
- 分離及び収集ゾーンがサイクロン式収集機を含む、請求項16に記載のシステム。
- 微細化ゾーンが、約0.1μm〜約10μmの範囲の粒径を有する微細化結晶性材料を供給するように構成されている、請求項16に記載のシステム。
- 微細化ゾーンが安全バリア内に収容されている、請求項16に記載のシステム。
- コンディショニング済み微細化結晶性粒子を保持室で収集するステップをさらに含む、請求項1から15のいずれか一項に記載の方法。
- 第2のコンディショニングガスを調製するステップと、コンディショニング済み微細化結晶性粒子が保持室中に維持されている間に第2のコンディショニングガスを前記コンディショニング済み微細化結晶性粒子と混合するステップとをさらに含み、第2のコンディショニングガスとコンディショニング済み微細化結晶性粒子の前記混合が、微細化結晶性粒子の第2のコンディショニングを実現するのに十分な時間で行われる、請求項35に記載の方法。
- コンディショニング済み粒子が絶えず流動状態で保持室内で維持される、請求項35及び36のいずれか一項に記載の方法。
- 微細化粒子の第2のコンディショニングが、アモルファス材料の存在の低減又は残留溶媒の量の低減の一方又は両方をもたらす、請求項35から37のいずれか一項に記載の方法。
- 第2のコンディショニングガスを調製するステップと、コンディショニング済み微細化結晶性粒子が保持室中に維持されている間に第2のコンディショニングガスを前記コンディショニング済み微細化結晶性粒子と混合するステップとをさらに含み、第2のコンディショニングガスとコンディショニング済み微細化結晶性粒子の前記混合が、微細化結晶性粒子の第2のコンディショニングを実現するのに十分な時間で行われる、請求項1から15のいずれか一項に記載の方法。
- 微細化粒子の第2のコンディショニングが、アモルファス材料の存在の低減又は残留溶媒の量の低減の一方又は両方をもたらす、請求項39に記載の方法。
- 微細化結晶性粒子がグリコピロニウム又は薬学的に許容可能なその塩を含む、請求項1に記載の方法。
- 微細化結晶性粒子が、フッ化物、塩化物、臭化物、ヨウ化物、硝酸、硫酸、リン酸、ギ酸、酢酸、トリフルオロ酢酸、プロピオン酸、酪酸、乳酸、クエン酸、酒石酸、リンゴ酸、マレイン酸、コハク酸、安息香酸、p−クロロ安息香酸、ジフェニル酢酸若しくはトリフェニル酢酸、o−ヒドロキシ安息香酸、p−ヒドロキシ安息香酸、1−ヒドロキシナフタレン−2−カルボン酸、3−ヒドロキシナフタレン−2−カルボン酸、メタンスルホン酸、及びベンゼンスルホン酸塩から選ばれる薬学的に許容可能な塩を含む、請求項41に記載の方法。
- グリコピロニウムの薬学的に許容可能な塩が、3−[(シクロペンチルヒドロキシフェニルアセチル)オキシ]−1,1−ジメチルピロリジニウムブロミドである、請求項42に記載の方法。
- 微細化結晶性粒子が、ブデソニド又は薬学的に許容可能なその塩を含む、請求項1に記載の方法。
- 溶媒の蒸気が、溶媒の飽和蒸気圧未満の蒸気圧で維持された溶媒を含む、請求項1に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361799956P | 2013-03-15 | 2013-03-15 | |
US61/799,956 | 2013-03-15 | ||
PCT/US2014/029489 WO2014144894A1 (en) | 2013-03-15 | 2014-03-14 | Methods and systems for conditioning of particulate crystalline materials |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016515931A JP2016515931A (ja) | 2016-06-02 |
JP2016515931A5 JP2016515931A5 (ja) | 2017-04-20 |
JP6454323B2 true JP6454323B2 (ja) | 2019-01-16 |
Family
ID=50487199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016503111A Active JP6454323B2 (ja) | 2013-03-15 | 2014-03-14 | 粒子状結晶性材料のコンディショニングのための方法及びシステム |
Country Status (18)
Country | Link |
---|---|
US (3) | US20140275517A1 (ja) |
EP (1) | EP2968152B2 (ja) |
JP (1) | JP6454323B2 (ja) |
KR (2) | KR102275109B1 (ja) |
CN (1) | CN105188679B (ja) |
AU (1) | AU2014228414B2 (ja) |
BR (1) | BR112015022784B1 (ja) |
CA (1) | CA2905542C (ja) |
ES (1) | ES2712988T5 (ja) |
HK (2) | HK1219059A1 (ja) |
IL (1) | IL240759B (ja) |
MX (1) | MX361286B (ja) |
MY (1) | MY178819A (ja) |
RU (1) | RU2696582C2 (ja) |
SG (1) | SG11201507286QA (ja) |
TR (1) | TR201902687T4 (ja) |
WO (1) | WO2014144894A1 (ja) |
ZA (1) | ZA201506176B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102275109B1 (ko) | 2013-03-15 | 2021-07-07 | 펄 테라퓨틱스 인코포레이티드 | 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템 |
CN108135851B (zh) | 2015-09-09 | 2022-03-15 | 维克多瑞有限公司 | 射流研磨方法 |
PT3490533T (pt) * | 2016-07-29 | 2020-07-21 | Inke Sa | Processo de estabilização do tamanho de partícula |
IT201600098452A1 (it) * | 2016-09-30 | 2018-03-30 | Micro Macinazione Sa | Apparecchiatura per la micronizzazione di materiale polveroso con capacita’ di prevenire incrostazioni |
Family Cites Families (158)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
US3175299A (en) * | 1961-08-02 | 1965-03-30 | American Sugar | Method of drying sugar crystals with acoustic energy and a gas |
US3994974A (en) | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
SE378109B (ja) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
US4187301A (en) | 1978-04-05 | 1980-02-05 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes |
CA1201114A (en) | 1980-02-15 | 1986-02-25 | Gordon H. Phillipps | Androstane carbothioates |
EP0057401B1 (en) | 1981-02-02 | 1984-08-01 | Schering Corporation | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
DE3268533D1 (en) * | 1981-07-24 | 1986-02-27 | Fisons Plc | Inhalation drugs, methods for their production and pharmaceutical formulations containing them |
ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
GB8432063D0 (en) | 1984-12-19 | 1985-01-30 | Riker Laboratories Inc | Physically modified steroids |
US5707634A (en) | 1988-10-05 | 1998-01-13 | Pharmacia & Upjohn Company | Finely divided solid crystalline powders via precipitation into an anti-solvent |
GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
EP0416950B1 (en) | 1989-09-08 | 1993-08-11 | Glaxo Group Limited | Medicaments |
IL95590A (en) | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
DE3931041C2 (de) | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
US5610163A (en) | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
ES2065701T3 (es) | 1990-09-10 | 1995-02-16 | Schering Corp | Furoato de mometasona monohidrato, procedimiento para fabricar el mismo y composiciones farmaceuticas. |
DE4108393A1 (de) | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
SE9101090D0 (sv) * | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
US5874063A (en) | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
AU659645B2 (en) | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
WO1993011773A1 (en) | 1991-12-18 | 1993-06-24 | Aktiebolaget Astra | New combination of formoterol and budesonide |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US5849263A (en) | 1993-03-30 | 1998-12-15 | Charlotte-Mecklenburg Hospital Authority | Pharmaceutical compositions containing alkylaryl polyether alcohol polymer |
GB9313642D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
ES2193186T3 (es) | 1993-12-02 | 2003-11-01 | Abbott Lab | Composiciones medicamentosas en aerosol para la utilizacion con gases propulsores sin cfc. |
SE9404080L (sv) | 1993-12-28 | 1995-06-29 | Ciba Geigy Ag | Förfarande för framställning av en optiskt ren enantiomer av formoterol |
US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
ATE165438T1 (de) | 1994-02-09 | 1998-05-15 | Kinerton Ltd | Verfahren zur trocknung eines materials aus einer lösung |
GB9413202D0 (en) | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
CZ288146B6 (en) | 1994-12-22 | 2001-05-16 | Astra Ab | Pharmaceutical aerosol preparation, process of its preparation and use |
US5612053A (en) | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
GB9507768D0 (en) | 1995-04-13 | 1995-05-31 | Glaxo Group Ltd | Method of apparatus |
KR19980703876A (ko) | 1995-04-14 | 1998-12-05 | 스티븐 엘. 허스트 | 분산성이 개선된 분말화된 약학적 조성물 |
US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
DE19614421C2 (de) | 1996-04-12 | 1999-12-16 | Biovision Gmbh | Verfahren zur Herstellung eines biodegradierbaren Knochenersatz- und Implantatwerkstoffes und biodegradierbarer Knochenersatz- und Implantatwerkstoff |
GB9610821D0 (en) | 1996-05-23 | 1996-07-31 | Glaxo Wellcome Inc | Metering apparatus |
US6054488A (en) | 1996-06-11 | 2000-04-25 | 3M Innovative Properties Company | Medicinal aerosol formulations of formoterol |
GB9612297D0 (en) | 1996-06-11 | 1996-08-14 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
US5886200A (en) | 1996-07-01 | 1999-03-23 | Schering Corporation | Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones |
US6068832A (en) | 1996-08-29 | 2000-05-30 | Schering Corporation | Chlorofluorocarbon-free mometasone furoate aerosol formulations |
US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
SE9700135D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
WO1998041193A1 (en) | 1997-03-20 | 1998-09-24 | Schering Corporation | Preparation of powder agglomerates |
US6129905A (en) | 1997-04-21 | 2000-10-10 | Aeropharm Technology, Inc. | Aerosol formulations containing a sugar as a dispersant |
US6010935A (en) | 1997-08-21 | 2000-01-04 | Micron Technology, Inc. | Self aligned contacts |
SE9703407D0 (sv) | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
ES2205560T5 (es) | 1997-09-29 | 2013-04-16 | Novartis Ag | Preparaciones estabilizadas para usar en inhaladores de dosis medida |
US6433040B1 (en) | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
US6946117B1 (en) | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
GB9808470D0 (en) † | 1998-04-22 | 1998-06-17 | Smithkline Beecham Plc | Novel process and apparatus |
US6260549B1 (en) | 1998-06-18 | 2001-07-17 | Clavius Devices, Inc. | Breath-activated metered-dose inhaler |
US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
CA2338680C (en) | 1998-08-04 | 2008-10-14 | Jago Research Ag | Medicinal aerosol formulations |
PT1131059E (pt) | 1998-11-13 | 2003-07-31 | Jago Res Ag | Po seco para inalacao |
GB9912639D0 (en) | 1999-05-28 | 1999-07-28 | Britannia Pharmaceuticals Ltd | Improvements in and relating to treatment of respiratory conditions |
GB9826284D0 (en) * | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
CA2356637C (en) | 1998-12-22 | 2011-09-13 | The University Of North Carolina At Chapel Hill | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
GB9902689D0 (en) | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
GB9903759D0 (en) | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
GB9904919D0 (en) | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
CZ298489B6 (cs) | 1999-03-05 | 2007-10-17 | Chiesi Farmaceutici S. P. A. | Prášek pro použití v inhalátoru |
SE9900833D0 (sv) | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
ES2193069T3 (es) | 1999-04-14 | 2003-11-01 | Glaxo Group Ltd | Formulacion farmaceutica en aerosol. |
US20100197719A1 (en) | 1999-05-12 | 2010-08-05 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
US6255320B1 (en) * | 1999-06-01 | 2001-07-03 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions |
DE60009695T2 (de) * | 1999-06-03 | 2004-09-23 | Eisai Co., Ltd. | Kristalline cabapenemderivate und pharmazeutische zubereitungen zur injektion |
MXPA01013168A (es) * | 1999-06-30 | 2002-07-30 | Inhale Therapeutic Syst | Proceso de secado por rocio para preparar polvos secos. |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
NZ500555A (en) | 1999-08-02 | 2000-11-24 | Hovione Int Ltd | Process for the preparation of mometasone furoate |
US6586008B1 (en) | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
DE60025019T2 (de) | 1999-10-29 | 2006-08-24 | Nektar Therapeutics, San Carlos | Trockenpulverzusammensetzungen mit verbesserter dispersivität |
US6596261B1 (en) | 2000-01-25 | 2003-07-22 | Aeropharm Technology Incorporated | Method of administering a medicinal aerosol formulation |
IT1317846B1 (it) | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
CA2382133C (en) | 2000-05-10 | 2010-11-23 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
US20060257324A1 (en) | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
US20040081627A1 (en) | 2000-10-09 | 2004-04-29 | Jinks Phillip A | Medicinal aerosol formulations |
US6908928B2 (en) | 2000-10-12 | 2005-06-21 | Bi Pharma Kg. | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
ATE517607T1 (de) | 2000-11-30 | 2011-08-15 | Vectura Ltd | Verfahren zur herstellung von partikeln zur verwendung in einer pharmazeutischen zusammensetzung |
GB0030074D0 (en) * | 2000-12-08 | 2001-01-24 | Univ London Pharmacy | Particulate inhalation carrier |
US20020141946A1 (en) | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
ITMI20010428A1 (it) | 2001-03-02 | 2002-09-02 | Chemo Breath S A | Composizioni ad uso inalatorio a base di formoterolo |
BR0208012A (pt) | 2001-03-20 | 2004-03-02 | Glaxo Group Ltd | Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma |
SK286394B6 (sk) | 2001-03-30 | 2008-09-05 | Jagotec Ag | Lekárske aerosólové prípravky |
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US6848197B2 (en) | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
DE10120484A1 (de) * | 2001-04-25 | 2002-10-31 | Degussa | Verfahren und Vorrichtung zur thermischen Behandlung von pulverförmigen Stoffen |
DE10130371A1 (de) | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
US20030018019A1 (en) | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
TWI324934B (en) | 2001-08-28 | 2010-05-21 | Schering Corp | Pharmaceutical compositions for the treatment of asthma |
DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
JP2006512044A (ja) | 2002-03-07 | 2006-04-13 | アバロン ファーマシューティカルズ,インコーポレイテッド | 化学療法のための標的としての癌関連遺伝子 |
DE10214264A1 (de) | 2002-03-28 | 2003-10-16 | Boehringer Ingelheim Pharma | HFA-Suspensionsformulierungen eines Anhydrats |
GB0207906D0 (en) | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
DE10216429A1 (de) | 2002-04-12 | 2003-10-23 | Boehringer Ingelheim Pharma | Arzneimittel enthaltend Steroide und ein neues Anticholinergikum |
MXPA04012410A (es) | 2002-06-12 | 2005-10-19 | Epigenesis Pharmaceuticals Inc | Composiciones, formulaciones y equipo para el tratamiento de enfermedades pulmonares y respiratorias con deshidroepiandrosteronas, esteroides y agentes antimuscarinicos. |
US7244742B2 (en) | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
DE10237739A1 (de) | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
WO2004035417A1 (en) | 2002-10-15 | 2004-04-29 | Cryovac, Inc. | A process for triggering, storing, and distributing an oxygen scavenger, and a stored oxygen scavenger |
US20040121003A1 (en) | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
DE10323966A1 (de) | 2003-05-27 | 2004-12-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen |
EP1635786A2 (en) | 2003-05-28 | 2006-03-22 | Nektar Therapeutics | Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat |
ES2383206T3 (es) | 2003-06-16 | 2012-06-19 | Nycomed Gmbh | Composición que comprende un tensioactivo pulmonar y sildenafilo para el tratamiento de neumopatías |
SE527190C2 (sv) | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid |
CA2533791C (en) | 2003-07-28 | 2012-05-22 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising betamimetics and an anticholinergic agent |
NZ545443A (en) | 2003-07-29 | 2010-04-30 | Boehringer Ingelheim Int | Combination of an aclidinium salt known as 3-(2-hydroxy-2,2-dithiophen-2-yl-acetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane and a steroid and its use to treat respiratory disorders by inhalation |
CN1829534A (zh) | 2003-07-29 | 2006-09-06 | 贝林格尔.英格海姆国际有限公司 | 包括β模拟物和抗胆碱能药的吸入药剂 |
WO2005013994A1 (en) | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising anticholinergics and a betamimetic |
US9308199B2 (en) | 2004-04-29 | 2016-04-12 | Honeywell International Inc. | Medicament formulations |
SE0303270L (sv) | 2003-12-03 | 2005-06-04 | Microdrug Ag | Metod för administration av tiotropium |
PL1713473T3 (pl) | 2004-02-06 | 2013-08-30 | Meda Pharma Gmbh & Co Kg | Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP |
JP5524442B2 (ja) | 2004-02-06 | 2014-06-18 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 呼吸器疾患の治療のための、抗コリン作用薬及びβ−模倣薬の新規併用薬 |
US20050287077A1 (en) | 2004-02-10 | 2005-12-29 | James E. Shipley | Process for preparing stable SOL of pharmaceutical ingredients and hydrofluorocarbon |
GB0409703D0 (en) † | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
AU2005247410A1 (en) * | 2004-05-20 | 2005-12-08 | Discovery Laboratories, Inc. | Methods , systems and devices for noninvasive pulmonary delivery |
BRPI0512146A (pt) | 2004-06-18 | 2008-02-12 | Novartis Vaccines & Diagnostic | métodos para o tratamento de uma infecção endobrÈnquica em um paciente, e de um paciente com fibrose cìstica, sofrendo de uma infecção endobrÈnquica |
GB0426301D0 (en) | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
US7915303B2 (en) | 2005-03-24 | 2011-03-29 | Sosei R&D Ltd. | Glycopyrronium salts and their therapeutic use |
JP2008534611A (ja) | 2005-03-30 | 2008-08-28 | シェーリング コーポレイション | 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法 |
WO2006114379A1 (de) | 2005-04-23 | 2006-11-02 | Boehringer Ingelheim International Gmbh | Arzneimittelkombination für die inhalation enthaltend neben einem anticholinergikum ein betamimetikum und ein steroid |
GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
EP1893203A2 (en) | 2005-05-31 | 2008-03-05 | Boehringer Ingelheim International GmbH | Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor |
EP1904219A4 (en) | 2005-07-15 | 2011-07-27 | Map Pharmaceuticals Inc | METHOD FOR FORMING PARTICLES |
CN100560598C (zh) | 2005-07-26 | 2009-11-18 | 上海奥锐特国际贸易有限公司 | 氟替卡松丙酸酯的合成方法 |
GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
PL2098248T3 (pl) | 2005-12-21 | 2012-11-30 | Meda Pharma Gmbh & Co Kg | Kombinacja antycholinergików, glukokortykoidów i beta2-agonistów do leczenia chorób zapalnych |
US8263645B2 (en) | 2006-02-03 | 2012-09-11 | Pari Pharma Gmbh | Disodium cromoglycate compositions and methods for administering same |
US20070202055A1 (en) | 2006-02-09 | 2007-08-30 | Julianne Berry | Pharmaceutical Formulations |
WO2007134964A1 (en) | 2006-05-24 | 2007-11-29 | Boehringer Ingelheim International Gmbh | Novel medicament combinations for the treatment of respiratory diseases |
GB0613161D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
GB0614621D0 (en) | 2006-07-24 | 2006-08-30 | 3M Innovative Properties Co | Metered dose dispensers |
EP1894568A1 (en) | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
CA2677573A1 (en) | 2007-02-19 | 2008-08-28 | Cipla Limited | Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid |
EP2036572A1 (en) | 2007-09-04 | 2009-03-18 | Novo Nordisk A/S | Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle |
GB0801876D0 (en) | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
FR2940162B1 (fr) | 2008-12-22 | 2011-02-25 | Boehm & Cie Ets | Outil de frappe multi-usages a mecanisme absorbant l'energie transmise au moyen de prehension |
WO2010097188A1 (en) | 2009-02-25 | 2010-09-02 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a salt of carmoterol and a corticosteroid |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
HUE047834T2 (hu) | 2009-05-29 | 2020-05-28 | Pearl Therapeutics Inc | Nyújtott hatású muszkarin antagonisták és nyújtott hatású béta 2 adrenerg receptor agonisták pulmonáris beadására alkalmas készítmények és ezekkel kapcsolatos eljárások és rendszerek |
JP2014504260A (ja) * | 2010-10-15 | 2014-02-20 | グラクソ グループ リミテッド | 集合ナノ粒子状薬物製剤、その製造及び使用 |
EP2749277A3 (en) | 2011-02-17 | 2014-08-27 | Cipla Limited | Combination of glycopyrronium and vilanterol |
JO3510B1 (ar) * | 2011-03-04 | 2020-07-05 | Heptares Therapeutics Ltd | استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب |
JP2014518871A (ja) | 2011-05-17 | 2014-08-07 | パール セラピューティクス,インコーポレイテッド | 2つ以上の活性薬剤を呼吸器に送達するための組成物、方法及びシステム |
US20120325942A1 (en) | 2011-06-27 | 2012-12-27 | General Electric Company | Jet milling of boron powder using inert gases to meet purity requirements |
KR102275109B1 (ko) | 2013-03-15 | 2021-07-07 | 펄 테라퓨틱스 인코포레이티드 | 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템 |
-
2014
- 2014-03-14 KR KR1020157028327A patent/KR102275109B1/ko active IP Right Grant
- 2014-03-14 EP EP14717628.3A patent/EP2968152B2/en active Active
- 2014-03-14 RU RU2015144286A patent/RU2696582C2/ru active
- 2014-03-14 MX MX2015013217A patent/MX361286B/es active IP Right Grant
- 2014-03-14 WO PCT/US2014/029489 patent/WO2014144894A1/en active Application Filing
- 2014-03-14 SG SG11201507286QA patent/SG11201507286QA/en unknown
- 2014-03-14 BR BR112015022784-8A patent/BR112015022784B1/pt active IP Right Grant
- 2014-03-14 CA CA2905542A patent/CA2905542C/en active Active
- 2014-03-14 CN CN201480026439.XA patent/CN105188679B/zh active Active
- 2014-03-14 ES ES14717628T patent/ES2712988T5/es active Active
- 2014-03-14 KR KR1020217007854A patent/KR102391332B1/ko active IP Right Grant
- 2014-03-14 MY MYPI2015703160A patent/MY178819A/en unknown
- 2014-03-14 TR TR2019/02687T patent/TR201902687T4/tr unknown
- 2014-03-14 US US14/213,834 patent/US20140275517A1/en not_active Abandoned
- 2014-03-14 AU AU2014228414A patent/AU2014228414B2/en active Active
- 2014-03-14 JP JP2016503111A patent/JP6454323B2/ja active Active
-
2015
- 2015-08-23 IL IL24075915A patent/IL240759B/en active IP Right Grant
- 2015-08-25 ZA ZA2015/06176A patent/ZA201506176B/en unknown
-
2016
- 2016-06-21 HK HK16107179.0A patent/HK1219059A1/zh unknown
- 2016-06-21 HK HK16107208.5A patent/HK1219223A1/zh unknown
-
2018
- 2018-01-17 US US15/873,779 patent/US20180344747A1/en not_active Abandoned
-
2020
- 2020-01-30 US US16/777,340 patent/US11471468B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11471468B2 (en) | Methods and systems for conditioning of particulate crystalline materials | |
Rehman et al. | Optimisation of powders for pulmonary delivery using supercritical fluid technology | |
EP2560620B1 (en) | A process for particle processing of active pharmaceutical ingredients | |
KR100951750B1 (ko) | 분무 건조 방법 및 그 조성물 | |
HRP20050546A2 (en) | Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation | |
US20040028619A1 (en) | Ihnalation particles incorporating a combination of two or more active ingredients | |
CN108135851B (zh) | 射流研磨方法 | |
WO2002028378A1 (en) | Combination particles for the treatment of asthma | |
US11219602B2 (en) | Method for making a micronized dry powder formulation of glycopyrrolate and magnesium stearate | |
NZ711200B2 (en) | Methods and systems for conditioning of particulate crystalline materials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170313 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170313 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170615 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20171006 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171016 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20171006 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180215 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180615 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181204 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181214 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6454323 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |